Open AccessBrolucizumab – A New Player In The Field Of Anti-VEGF Therapy Of Neovascular Age-Related Macular Degeneration. A Review
Author(s) -
Martin Šín
Publication year - 2022
Publication title -
česká a slovenská oftalmologie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.178
H-Index - 11
eISSN - 1805-4447
pISSN - 1211-9059
DOI - 10.31348/2021/19
Subject(s) - macular degeneration , aflibercept , medicine , choroidal neovascularization , tolerability , vascular endothelial growth factor , dosing , bevacizumab , ranibizumab , regimen , pharmacology , ophthalmology , adverse effect , chemotherapy , vegf receptors